Search Results

• • 4 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene

  Authors:Maria del Mar Noblejas-Lopez, Sara Morcillo-Garcia, Cristina Nieto-Jimenez, Miriam Nuncia-Cantarero, Balazs Gyorffy, Eva M. Galan-Moya, et al.From:PLoS ONE (Vol. 13, Issue 11) Peer-Reviewed

  Nov. 28, 20184,034 words Report 1370LRegulation of transcription is a key process in cellular homeostasis. It depends on regulators that either repress or stimulate the transcription of genes, therefore controlling different biological functions. The...

• Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

  Authors:Maria del Mar Noblejas-Lopez, Cristina Nieto-Jimenez, Miguel Burgos, Monica Gomez-Juarez, Juan Carlos Montero, Azucena Esparis-Ogando, et al.From:Journal of Experimental & Clinical Cancer Research (Vol. 38, Issue 1) Peer-Reviewed

  Aug. 30, 20194,225 words Report 1400LBackground Triple negative breast cancer (TNBC) is an incurable disease where novel therapeutic strategies are needed. Proteolysis targeting chimeric (PROTAC) are novel compounds that promote protein degradation by...

• Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.

  Authors:Sara Morcillo-Garcia, Maria del Mar Noblejas-Lopez, Cristina Nieto-Jimenez, Javier Perez-Peña, Miriam Nuncia-Cantarero, Balázs Gyorffy, et al.From:PLoS ONE (Vol. 14, Issue 4) Peer-Reviewed

  Apr. 16, 20194,192 words Report 1390LPurpose Epigenetic regulating proteins like histone methyltransferases produce variations in several functions, some of them associated with the generation of oncogenic processes. Mutations of genes involved in these...

• MZ1 co-operates with trastuzumab in HER2 positive breast cancer.

  Authors:María del Mar Noblejas-López, Cristina Nieto-Jiménez, Eva M. Galán-Moya, David Tebar-García, Juan Carlos Montero, Atanasio Pandiella, et al.From:Journal of Experimental & Clinical Cancer Research (Vol. 40, Issue 1) Peer-Reviewed

  Mar. 19, 20216,327 words Article 1510LBackground Although the anti-HER2 antibody trastuzumab augments patient survival in HER2+ breast cancer, a relevant number of patients progress to this treatment. In this context, novel drug combinations are needed to...